The domestic equity benchmarks continued to trade with deep cuts in early afternoon trade. The Nifty continued to trade below the 17,350 mark. FMCG shares witnessed some bit of bargain buying. Investor sentiments were dented tracking weak global cues as Fed Chair in his address last week flagged the likely need for restrictive monetary policy to curb high inflation.
At 12:18 IST, the barometer index, the S&P BSE Sensex, was down 797.4 points or 1.36% to 58,036.47. The Nifty 50 index lost 229.45 points or 1.28% to 17,334.50.
In the broader market, the S&P BSE Mid-Cap index declined 1.04% while the S&P BSE Small-Cap index fell 0.73%.
The market breadth remained weak. On the BSE, 1,214 shares rose and 2,186 shares fell. A total of 186 shares were unchanged.
Derivatives:
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, jumped 9.77% to 20. The Nifty 29 September 2022 futures were trading at 17,388.40, at a premium of 53.9 points as compared with the spot at 17,334.50.
The Nifty option chain for the 29 September 2022 expiry showed maximum Call OI of 18.9 lakh contracts at the 18,000 strike price. Maximum Put OI of 37.3 lakh contracts were seen at 16,000 strike price.
Buzzing Index:
The Nifty FMCG index rose 0.42% to 42,949.25. The index had declined 0.54% in the past two sessions.
Colgate-Palmolive (India) (up 4.24%), Godrej Consumer Products (up 1.53%), Marico (up 1.28%), Dabur India (up 1.23%) and Nestle India (up 1.02%) were the top gainers.
Among the other gainers were Britannia Industries (up 1.01%), Radico Khaitan (up 0.95%), Hindustan Unilever (up 0.93%), Tata Consumer Products (up 0.88%).
Meanwhile, Varun Beverages (down 2.91%), Procter & Gamble Hygiene and Health Care (down 0.91%) and United Spirits (down 0.74%) edge lower.
Stocks in Spotlight:
SRF rose 0.65%. The company said that it has commissioned and capitalized the second BOPP Film Line & Metallizer at Indore on 25 August 2022 at an aggregate cost of approximately Rs 446 crore.
Alembic Pharmaceuticals gained 0.86%. The drugmaker said that it has received final approval from the US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Chlorthalidone Tablets USP.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app